Vernalis PLC Block listing Interim Review (2209L)
September 29 2016 - 10:00AM
UK Regulatory
TIDMVER
RNS Number : 2209L
Vernalis PLC
29 September 2016
BLOCK LISTING SIX MONTHLY RETURN
VERNALIS PLC (the "Company")
29 September 2016
Vernalis plc (LSE: VER) provides the following update in
accordance with Schedule Six of the AIM Rules for Companies
regarding its existing block listing arrangements:
Name of applicant: Vernalis plc
----------------------------------- ---------------------------------------------------
Name of scheme(s): 2007 Long Term Incentive Scheme
("LTIP") and the Savings Related
Share Option Plan 2003 ("SAYE")
----------------------------------- ---------------------------------------------------
Period of return (from From: 29/Mar/2016 To: 29/Sept/2016
/ to):
----------------------------------- -------------------------- -----------------------
Balance of unallotted securities Total of 2,243,318 Ordinary 1p
under scheme(s) from previous Shares, split:
return: * Under LTIP = 2,243,318 Ordinary 1p Shares
* Under SAYE = NIL Ordinary 1p Shares
----------------------------------- ---------------------------------------------------
Plus: The amount by which NIL
the block scheme(s) has
been increased or application
has been made to increase
since the date of the last
return (if any increase
has been applied for):
----------------------------------- ---------------------------------------------------
Less: Number of securities Total of 1,074,958 Ordinary 1p
issued/allotted under scheme(s) Shares, split:
during period: * Under LTIP = 1,074,958 Ordinary 1p Shares
* Under SAYE = NIL Ordinary 1p Shares
----------------------------------- ---------------------------------------------------
Less: Number of securities
forfeited under scheme(s)
during period: 767,304
----------------------------------- ---------------------------------------------------
Equals: Balance under scheme(s) Total of 401,056 Ordinary 1p Shares,
not yet issued/allotted split:
at end of period: * Under LTIP = 401,056 Ordinary 1p Shares
* Under SAYE = NIL Ordinary 1p Shares
----------------------------------- ---------------------------------------------------
Number and class of securities No. of Ordinary Date on which Shares
originally admitted and 1p Shares were Admitted to
the date of admission (including Trading
any additions): ---------------- ---------------------
350,000 6 November 2013,
plus
---------------- ---------------------
1,049,317 12 May 2014, plus
---------------- ---------------------
1,058,184 12 May 2015, plus
---------------- ---------------------
1,638,364 30 September 2015
---------------- ---------------------
1,189,296 1 April 2016
---------------- ---------------------
----------------------------------- ---------------------------------------------------
-- ends -
Enquiries:
Vernalis plc: +44 (0) 118 938 0015
Ian Garland, Chief Executive Officer
David Mackney, Chief Financial Officer
Canaccord Genuity Limited (Nominated
Adviser): +44 (0) 20 7523 8000
Dr Julian Feneley
Henry Fitzgerald-O'Connor
Rupert Winckler
Emma Gabriel
Shore Capital (Joint Broker): +44 (0) 20 7408 4090
Bidhi Bhoma
Toby Gibbs
FTI Consulting: +44 (0) 20 3727 1000
Ben Atwell
Simon Conway
Stephanie Cuthbert
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage
pharmaceutical company with significant expertise in drug
development. The Group has three approved products: Tuzistra(R) XR
targeting the US prescription cough cold market; MOXATAG(R) , a
once-a-day formulation of the antibiotic, amoxicillin, indicated
for the treatment of tonsillitis and/or pharyngitis secondary to
Streptococcus pyogenes and frovatriptan for the acute treatment of
migraine. It has an exclusive licensing agreement to develop and
commercialise multiple novel products focussed on the US
prescription cough cold market as well as eight programmes in its
NCE development pipeline. Vernalis has also significant expertise
in fragment and structure based drug discovery which it leverages
to enter into collaborations with larger pharmaceutical companies.
The Company's technologies, capabilities and products have been
endorsed over the last five years by collaborations with leading
pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK,
Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and
Tris.
For further information about Vernalis, please visit
www.vernalis.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRLLMMTMBATBBF
(END) Dow Jones Newswires
September 29, 2016 10:00 ET (14:00 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Apr 2024 to May 2024
Vernalis (LSE:VER)
Historical Stock Chart
From May 2023 to May 2024